Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:CTIC

CTI BioPharma (CTIC) Stock Price, News & Analysis

CTI BioPharma logo

About CTI BioPharma Stock (NASDAQ:CTIC)

Advanced Chart

Key Stats

Today's Range
$9.09
$9.09
50-Day Range
$8.91
$9.10
52-Week Range
$4.01
$9.10
Volume
N/A
Average Volume
4.50 million shs
Market Capitalization
$1.20 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive CTIC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CTI BioPharma and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CTIC Stock News Headlines

He Called Nvidia at $1.10. Now, He Says THIS Stock Will…
The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvidia at $1.10 reveals AI’s Next Magnificent Seven… including one stock he says could become America’s next trillion-dollar giant.tc pixel
See More Headlines

CTIC Stock Analysis - Frequently Asked Questions

CTI BioPharma Corp. (NASDAQ:CTIC) released its quarterly earnings results on Monday, March, 6th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by $0.04. The biopharmaceutical company earned $21.08 million during the quarter, compared to analyst estimates of $24.88 million.
Read the conference call transcript
.

Shares of CTI BioPharma reverse split on Tuesday, January 3rd 2017.The 1-10 reverse split was announced on Friday, December 9th 2016. The number of shares owned by shareholders was adjusted after the market closes on Friday, December 30th 2016. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that CTI BioPharma investors own include Edap Tms (EDAP), Energous (WATT), Adverum Biotechnologies (ADVM), Weatherford International (WFT), XOMA Royalty (XOMA), Advanced Micro Devices (AMD) and Sorrento Therapeutics (SRNE).

Company Calendar

Last Earnings
3/06/2023
Today
8/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CTIC
Previous Symbol
NASDAQ:CTICD
CIK
891293
Employees
127
Year Founded
1992

Profitability

EPS (Trailing Twelve Months)
($0.58)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$92.99 million
Net Margins
-91.38%
Pretax Margin
-91.38%
Return on Equity
N/A
Return on Assets
-55.82%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.27
Quick Ratio
1.26

Sales & Book Value

Annual Sales
$53 million
Price / Sales
22.62
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.14) per share
Price / Book
-64.93

Miscellaneous

Outstanding Shares
131,880,000
Free Float
121,844,000
Market Cap
$1.20 billion
Optionable
Optionable
Beta
0.83

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:CTIC) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners